Questions related to Healthcare Market Research
Could you please recommend a good topic for my MBA-Dissertation mainly around Pharmaceutical marketing. I believe the Covid-19 will significantly impact the way Pharma marketing operated earlier.
The brand managers/digital marketers would probably struggle to figure out the balanced operating model in a post COVID-19 world to commercialize their brand in a highly regulated space (B2B2C) which was primarily driven by sales reps. It would be interesting to know how pandemic has transformed the prescriber behavior and will they be open for sales reps visits which remained virtual for considerable time.
Is it possible to apply relational marketing in health care industry in order to maximize patients fidelity?
It has to do with the healthcare marketing and the research will take place in a private hospital. I actually need the proper literature review. Thank you in advance.
I am about to dig myself into & conduct a research on health marketing, more specifically health-consciousness & prevention in general. I would be more than happy to know which the top relevant papers in this field are. What is the best scale to measure health-consciousness & prevention in general?
I will do my research in Hungary. Should you be interested to collaborate to compare research findings in different countries/cultures, please let me know.
Thanks in advance.
Does anybody have information on where to find good market analysis research (revenues, future growth, etc.) on cell therapy. Interested particularly in Europe.
Gemifloxacin is the updated fluoroquinolone and promptly carries the highest efficacy over any other drug in respiratory tract infections or pneumonia. It has 5 folds more affinity than ciprofloxacin in binding and inhibiting bacterial topisomerase-IV and thus ensures less microbial resistance than ciprofloxacin. All clinical trials have established gemifloxacin as a potent and effective antibiotic in RTI. Its safety margin is almost equal to ciprofloxacin.
But I wonder, the market shows gemifloxacin as a potential negative growth medicine for a long time.